INSIGHTS ON DRUG DEVELOPMENT
-
Recombinant Protein Process Development And Scale-Up
Discover a resin for recombinant protein purification with a standardized protocol that streamlines workflows from lab to production, which saves time and enhances efficiency across development stages.
-
Mitigating Early Development Risks
Discover how the efficient screening of biologic candidates accelerates the discovery process, reduces costs, and improves the likelihood of commercializing safe and effective drugs.
-
NGS Identification Of Internal Tandem Duplications In FLT3
Accurately identifying genetic duplications in leukemia requires more than conventional sequencing. See how advanced enrichment and analysis approaches enable deeper insight into variant structure.
-
Complementary Methodologies For Analysis Of NISTmAb Impurities
Gain insight into how SEC and CE‑SDS complement each other to assess monoclonal antibody size variants, offering stronger insight into aggregates, fragments, and overall purity.
-
Evaluating Compound Toxicity Effects On Healthy Intestinal Organoids3/24/2025
3D organoids enhance drug toxicity prediction and are crucial for anti-cancer drug development. Examine a method using 3D mouse intestinal organoids that aims to provide vital data on intestinal toxicity.
-
mRNA Manufacturing With Fed-Batch In Vitro Transcription2/13/2026
A milliliter-scale approach to IVT optimization reveals how controlled feeding, precise pH management, and real-time monitoring can boost mRNA yield and streamline scale-up to larger bioreactor volumes.
-
Integration From Formulation Development To Manufacturing, Packaging2/27/2025
Adare Pharma Solutions' Pessano, Italy facility offers 220,000 sq. ft. of end-to-end services, including R&D, formulation development, clinical and commercial manufacturing, packaging, and advanced analytical capabilities.
-
384-Well Microplate Time Resolved Fluorescence (TRF) Immunoassay9/18/2024
Examine how innovative sandwich ELISAs in a 384-well format can be utilized with a sensitive reader for high-throughput screening to quantify Human IgG and IFN gamma.
-
Collaboration An Untapped Fuel For Driving Biopharma R&D10/20/2025
Biopharma’s future depends on collaboration. Discover how cross-industry partnerships and shared resources can accelerate innovation, overcome talent gaps, and strengthen the global R&D ecosystem.
DRUG DEVELOPMENT SOLUTIONS
-
The addition of global Sterile Fill-Finish and extensive lyophilization capabilities ensures that we are able to build on our enviable reputation and deliver on our promise of delivering life-changing therapies to patients worldwide.
-
Developing ophthalmic drugs demands precision and compliance. Explore a specialized excipient portfolio that supports optimal formulation to enhance stability, sterility, and patient comfort.
-
Learn about a solution for next-generation in vitro models that leverages cutting-edge organ-on-a-chip technology to emulate human biology with unparalleled accuracy compared to conventional models.
-
Rapid, high-throughput IgG quantification assay. Available in 96 & 384-well microplate options.
-
MaxPeak™ Premier Columns utilize MaxPeak High Performance Surfaces that are designed to increase analyte recovery, sensitivity, and reproducibility by minimizing analyte/surface interactions that can lead to sample losses.